Legato Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Legato Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,364	Closed	-$2.45M	–	637
2024 Q4	$2.45M	Buy	29,364 +9,541	+48%	+$784K	0.32%	68
2024 Q3	$1.45M	Sell	19,823 -4,759	-19%	-$358K	0.18%	187
2024 Q2	$1.68M	Buy	24,582 +9,923	+68%	+$688K	0.23%	155
2024 Q1	$1.01M	Buy	14,659 +3,197	+28%	+$220K	0.12%	269
2023 Q4	$821K	Buy	11,462 +6,491	+131%	+$373K	0.11%	309
2023 Q3	$259K	Sell	4,971 -14,882	-75%	-$867K	0.04%	494
2023 Q2	$1.26M	Buy	+19,853	New	+$1.24M	0.17%	198
2023 Q1	–	Sell	-14,487	Closed	-$767K	–	536
2022 Q4	$767K	Buy	+14,487	New	+$726K	0.15%	243
2021 Q3	–	Sell	-10,270	Closed	-$419K	–	330
2021 Q2	$419K	Buy	+10,270	New	+$380K	0.06%	266

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Legato Capital Management's ITCI Position: Q1 2025 in Review

Legato Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 29,364 shares — an estimated $2.45M sold.

Legato Capital Management first reported a position in ITCI in Q2 2021 and held it in 9 quarters. The position peaked at $2.45M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Legato Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Legato Capital Management sold 29,364 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.45M.
Legato Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 9 quarters.
Legato Capital Management's Intra-Cellular Therapies Inc. position peaked at $2.45M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.